In Vitro Susceptibility of a Large Collection of Candida Strains Against Fluconazole and Voriconazole by Using the CLSI Disk Diffusion Assay

Mycopathologia

Volumn 171, Issue 6, 2011, Pages 411-416

  Azevedo, Ana Carolina ^a   Bizerra, Fernando César ^a   da Matta, Daniel Arquimedes ^a   de Almeida, Leila Paula ^a   Rosas, Robert ^a   Colombo, Arnaldo Lopes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Candida spp.; Disk diffusion; Fluconazole; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; BRAZIL; CANDIDA; CANDIDIASIS; DISK DIFFUSION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGY;

ANTIFUNGAL AGENTS; BRAZIL; CANDIDA; CANDIDIASIS; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS;

EID: 79955746095     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9387-1     Document Type: Article

References (43)

1. Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006; 44(8): 2816-23.
2. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8. 5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007; 45(6): 1735-45.
3. da Matta VL, de Souza Carvalho Melhem M, Colombo AL, Moretti ML, Rodero L, Duboc de Almeida GM, et al. Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob Agents Chemother. 2007; 51(4): 1573-6.
4. Colombo AL, Janini M, Salomao R, Medeiros EA, Wey SB, Pignatari AC. Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the division of infectious diseases, UNIFESP. An Acad Bras Cienc. 2009; 81(3): 571-87.
5. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement-third edition, M27-S3. Wayne, PA; 2008.
6. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-third edition, M27-A3. Wayne, PA; 2008.
7. Barry AL, Pfaller MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol. 2000; 38(9): 3457-9.
8. Barry AL, Pfaller MA, Rennie RP, Fuchs PC, Brown SD. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 2002; 46(6): 1781-4.
9. Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, del Palacio A, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol. 2003; 41(12): 5623-32.
10. Pfaller MA, Barry A, Bille J, Brown S, Ellis D, Meis JF, et al. Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol. 2004; 42(4): 1716-8.
11. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK global antifungal surveillance program. Diagn Microbiol Infect Dis. 2009; 65(1): 27-34.
12. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol. 2005; 43(10): 5208-13.
13. Clinical and Laboratory Standards Institute (CLSI). Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard, M44-A. Wayne, PA; 2004.
14. Clinical and Laboratory Standards Institute (CLSI). Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts. Informational supplement, M44-S2. Wayne, PA; 2007.
15. Clinical and Laboratory Standards Institute (CLSI). Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guideline-second edition, M44-A2. Wayne, PA; 2009.
16. Clinical and Laboratory Standards Institute (CLSI). Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts. Informational supplement, M44-S3. Wayne, PA; 2009.
17. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother. 2003; 47(5): 1647-51.
18. Godoy P, Tiraboschi IN, Severo LC, Bustamante B, Calvo B, Almeida LP, et al. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz. 2003; 98(3): 401-5.
19. Antunes AG, Pasqualotto AC, Diaz MC, d'Azevedo PA, Severo LC. Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev Inst Med Trop Sao Paulo. 2004; 46(5): 239-41.
20. da Matta DA, de Almeida LP, Machado AM, Azevedo AC, Kusano EJ, Travassos NF, et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis. 2007; 57(4): 399-404.
21. Passos XS, Costa CR, Araujo CR, Nascimento ES, e Souza LK, Fernandes Ode F, et al. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia. 2007; 163(3): 145-51.
22. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia. 2001; 151(1): 5-10.
23. Fricker-Hidalgo H, Vandapel O, Duchesne MA, Mazoyer MA, Monget D, Lardy B, et al. Comparison of the new API Candida system to the ID 32C system for identification of clinically important yeast species. J Clin Microbiol. 1996; 34(7): 1846-8.
24. Ramani R, Gromadzki S, Pincus DH, Salkin IF, Chaturvedi V. Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates. J Clin Microbiol. 1998; 36(11): 3396-8.
25. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: 10. 5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009; 47(1): 117-23.
26. Colombo AL, Da Matta D, De Almeida LP, Rosas R. Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method. Braz J Infect Dis. 2002; 6(3): 118-23.
27. Pfaller MA, Hazen KC, Messer SA, Boyken L, Tendolkar S, Hollis RJ, et al. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol. 2004; 42(8): 3607-12.
28. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006; 44(3): 819-26.
29. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006; 19(2): 435-47.
30. Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis. 2005; 9(5): 411-8.
31. Girao E, Levin AS, Basso M, Gobara S, Gomes LB, Medeiros EA, et al. Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999-2003. Int J Infect Dis. 2008; 12(6): e145-6.
32. Franca JC, Ribeiro CE, Queiroz-Telles F. Candidemia in a Brazilian tertiary care hospital: incidence, frequency of different species, risk factors and antifungal susceptibility. Rev Soc Bras Med Trop. 2008; 41(1): 23-8.
33. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK global antifungal surveillance program. Diagn Microbiol Infect Dis. 2010; 67(2): 162-71.
34. Pasqualotto AC, Zimerman RA, Alves SH, Aquino VR, Branco D, Wiltgen D, et al. Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil. Infect Control Hosp Epidemiol. 2008; 29(9): 898-9.
35. Andrews JI, Fleener DK, Messer SA, Hansen WF, Pfaller MA, Diekema DJ. The yeast connection: is Candida linked to breastfeeding associated pain? Am J Obstet Gynecol. 2007; 197(4): e421-4.
36. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1): 133-63.
37. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J Clin Microbiol. 2008; 46(2): 515-21.
38. Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006; 44(10): 3578-82.
39. Colombo AL, Melo AS, Crespo Rosas RF, Salomao R, Briones M, Hollis RJ, et al. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis. 2003; 46(4): 253-7.
40. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001; 150(3): 101-15.
41. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002; 46(6): 1704-13.
42. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003; 36(5): 630-7.
43. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006; 44(5): 1740-3.